Siadat SD, Salmani AS, Aghasadeghi MR. Brucellosis vaccines: an overview. IntechOpen; 2012. doi:
10.5772/38812.
Bahador A, Esmaeili D, Mansoori N, Mahdavi M. Protection against Brucella abortus 544 Strain Infection in BALB/c Mice by Subcutaneouse Administration of Multicomponent Vaccine of rCagA Conjugated with LPS + CpG. J Pure Appl Microbiol. 2013;7(3):1809-1819.
Pasquevich KA, Garcia Samartino C, Coria LM, et al. The protein moiety of
Brucella abortus outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells in vivo, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis. J Immunol. 2010;184(9):5200-5212. doi:
10.4049/jimmunol.0902209.
Zheng WY, Wang Y, Zhang ZC, Yan F. Immunological characteristics of outer membrane protein omp31 of goat Brucella and its monoclonal antibody. Genet Mol Res. 2015;14(4):11965-11974. doi:
10.4238/2015.October.5.10.
Ghasemi A, Salari MH, Zarnani AH, et al. Immune reactivity of Brucella melitensis-vaccinated rabbit serum with recombinant Omp31 and DnaK proteins. Iran J Microbiol. 2013;5(1):19-23.
Basiri H, Akbari N, Azizpour M, Hosseini SD, Behrozikhah AM, Eskandari S. Amplification, cloning and expression of Brucella melitensis bp26 gene (OMP28) isolated from Markazi province (Iran) and purification of Bp26 Protein. Arch Razi Inst. 2013;68(2):111-116. doi:
10.7508/ari.2013.02.004.
Yao L, Wu CX, Zheng K, et al. Immunogenic response to a recombinant pseudorabies virus carrying bp26 gene of Brucella melitensis in mice. Res Vet Sci. 2015;100:61-67. doi:
10.1016/j.rvsc.2015.03.030.
Cassataro J, Pasquevich K, Bruno L, Wallach JC, Fossati CA, Baldi PC. Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae. Clin Diagn Lab Immunol. 2004;11(1):111-114. doi:
10.1128/CDLI.11.1.111-114.2004.
Vizcaino N, Cloeckaert A, Zygmunt MS, Dubray G. Cloning, nucleotide sequence, and expression of the Brucella melitensis omp31 gene coding for an immunogenic major outer membrane protein. Infect Immun. 1996;64(9):3744-3751.
Ogorodnik E, Raffaniello RD. Analysis of the 3’-variable region of the cagA gene from Helicobacter pylori strains infecting patients at New York City hospitals. Microb Pathog. 2013;56:29-34. doi:
10.1016/j.micpath.2012.10.003.
Dorneles EM, Sriranganathan N, Lage AP. Recent advances in
Brucella abortus vaccines. Vet Res. 2015;46:76. doi:
10.1186/s13567-015-0199-7.
Yang X, Skyberg JA, Cao L, Clapp B, Thornburg T, Pascual DW. Progress in Brucella vaccine development. Front Biol (Beijing). 2013;8(1):60-77. doi:
10.1007/s11515-012-1196-0.
Abkar M, Lotfi AS, Amani J, et al. Survey of Omp19 immunogenicity against
Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization. Vet Res Commun. 2015;39(4):217-228. doi:
10.1007/s11259-015-9645-2.
Tabynov K, Sansyzbay A, Kydyrbayev Z, et al. Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection. Virol J. 2014;11:69. doi:
10.1186/1743-422X-11-69.
Cassataro J, Pasquevich KA, Estein SM, et al. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine. 2007;25(22):4437-4446. doi:
10.1016/j.vaccine.2007.03.028.
Wang W, Wu J, Qiao J, et al. Evaluation of humoral and cellular immune responses to BP26 and OMP31 epitopes in the attenuated Brucella melitensis vaccinated sheep. Vaccine. 2014;32(7):825- 833. doi:
10.1016/j.vaccine.2013.12.028.
Amani J, Mousavi Gargari SL, Rafati S, Salmanian AH. In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications. Theor Biol Med Model. 2009;6:28. doi:
10.1186/1742-4682-6-28.
Amet N, Lee HF, Shen WC. Insertion of the designed helical linker led to increased expression of tf-based fusion proteins. Pharm Res. 2009;26(3):523-528. doi:
10.1007/s11095-008-9767-0.
Bai Y, Shen WC. Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization. Pharm Res. 2006;23(9):2116- 2121. doi:
10.1007/s11095-006-9059-5.
Baloria U, Akhoon BA, Gupta SK, Sharma S, Verma V. In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer. Amino Acids. 2012;42(4):1349- 1360. doi:
10.1007/s00726-010-0830-x.
Cai H, Li Y, Zhang H, Feng F. [Effects of gene design on recombinant protein expression: a review]. Sheng Wu Gong Cheng Xue Bao. 2013;29(9):1201-1213.
Klompus S, Solomon G, Gertler A. A simple novel method for the preparation of noncovalent homodimeric, biologically active human interleukin 10 in Escherichia coli-enhancing protein expression by degenerate PCR of 5’ DNA in the open reading frame. Protein Expr Purif. 2008;62(2):199-205. doi:
10.1016/j.pep.2008.07.013.